Cellectar Biosciences(CLRB) - 2024 Q2 - Quarterly Report

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.00001 CLRB NASDAQ Capital Market U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [mark one] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ ...